BioCentuty reports:
House moves closer to Senate on PDUFA
The U.S. House Energy and Commerce Committee posted a new draft PDUFA reauthorization bill that is more closely aligned with the Senate PDUFA bill than previous versions. Changes that reflect the Senate bill include dropping sections that would add jobs creation and economic development language to FDA's mission and adding a section that would create an expedited development pathway for breakthrough drugs.
However, several items in the House draft bill are still not in the pending Senate version, including provisions to increase public participation in crafting guidance documents and creation of a new priority review voucher system to encourage development of therapies for rare pediatric cancers. The House draft also requires that FDA provide Congress a 60-day notice prior to issuing guidance on the regulation of laboratory-developed tests. The Energy and Commerce Committee's health subcommittee is scheduled to meet Tuesday (today) to deliberate on the draft bill.
